| Mr Jack Weitzman, LCSW | |
|
1215 Fountain St, Alameda, CA 94501-4824 | |
| (408) 396-6191 | |
| (408) 972-6494 |
| Full Name | Mr Jack Weitzman |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 1215 Fountain St, Alameda, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891852794 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | LN009294 (California) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Managing Myeloma is pleased to announce the launch of the Myeloma Treatment Resource at the annual American Society of Clinical Oncology meeting in Chicago. The MTR, developed by the Managing Myeloma multidisciplinary scientific advisors, is a compilation of convenient, unique tools and resources essential for practitioners treating patients with multiple myeloma.
Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) and Stanford University School of Medicine will collaborate in a new consortium funded by the National Heart, Lung and Blood Institute (NHLBI) to develop stem cell and regenerative medicine therapies. GICD investigators, led by GICD Director Deepak Srivastava, MD, will collaborate with a Stanford team led by Robert Robbins, MD, professor and chair of cardiothoracic surgery, to investigate how to use induced pluripotent stem cells, or iPS cells, to repair damaged heart muscle.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.
Emotional or behavioral problems may explain why some adolescents with psychotic symptoms find it hard to interact socially, researchers highlight.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jack Weitzman, LCSW 1215 Fountain St, Alameda, CA 94501-4824 Ph: (408) 396-6191 | Mr Jack Weitzman, LCSW 1215 Fountain St, Alameda, CA 94501-4824 Ph: (408) 396-6191 |
News Archive
Managing Myeloma is pleased to announce the launch of the Myeloma Treatment Resource at the annual American Society of Clinical Oncology meeting in Chicago. The MTR, developed by the Managing Myeloma multidisciplinary scientific advisors, is a compilation of convenient, unique tools and resources essential for practitioners treating patients with multiple myeloma.
Scientists at the Gladstone Institute of Cardiovascular Disease (GICD) and Stanford University School of Medicine will collaborate in a new consortium funded by the National Heart, Lung and Blood Institute (NHLBI) to develop stem cell and regenerative medicine therapies. GICD investigators, led by GICD Director Deepak Srivastava, MD, will collaborate with a Stanford team led by Robert Robbins, MD, professor and chair of cardiothoracic surgery, to investigate how to use induced pluripotent stem cells, or iPS cells, to repair damaged heart muscle.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.
Emotional or behavioral problems may explain why some adolescents with psychotic symptoms find it hard to interact socially, researchers highlight.
› Verified 9 days ago
Ms. Krista Coffman Arrington, LCSW LEP Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 246 Oyster Pond Rd, Alameda, CA 94502 Phone: 510-484-9082 | |
Ms. Riva Star Gardner, ASW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2325 Clement Ave Ste A, Alameda, CA 94501 Phone: 510-629-6300 | |
Mrs. Michelle Macarai, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1300 Hansen Ave, Alameda, CA 94501 Phone: 510-205-1243 | |
Mr. Dan Gary Wertheimer, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1901 Shoreline Drive, Apt 303, Alameda, CA 94510 Phone: 510-995-8971 | |
Ms. Margaret Ann Lucas, LCSW , MFT Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1429 Oak St, Alameda, CA 94501 Phone: 510-522-6554 Fax: 510-521-6729 | |
Elizabeth Ann Hoch, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 339 Broadway, #104, Alameda, CA 94501 Phone: 510-407-7799 | |
Christine Swartwout Kovach, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3215 Encinal Ave, Ste. K, Alameda, CA 94501 Phone: 510-364-3723 |